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Background:  Withdrawal movement during rocuronium injection is a common, unresolved adverse effect.  We aimed 
to investigate the effect of IV acetaminophen pretreatment on withdrawal movement during rocuronium injection.
Methods:  This study enrolled 120 American Society of Anesthesiologists (ASA) I-II patients undergoing general 
anesthesia.  They were randomly assigned to three treatment groups. After occluding venous drainage using a 
tourniquet on the upper arm, the saline group received 5 ml of 0.9% sodium chloride solution, the lidocaine group 
received 40 mg of lidocaine, and the acetaminophen group received 50 mg of acetaminophen.  During injection 
of pretreatment drug, pain was assessed on a four-point scale.  The tourniquet was released after 120 seconds and 
anesthesia was performed using thiopental sodium 5 mg/kg followed by rocuronium 0.6 mg/kg. The withdrawal 
movement was graded on a four-point scale in a double-blind manner. 
Results:  The incidence of pain on pretreatment injection in saline, lidocaine, and acetaminophen groups was 7.7%, 
5.1%, and 2.5%, respectively.  The incidence of withdrawal movements was 77.5% in saline group, 32.5% in lidocaine 
group, and 37.5% in acetaminophen group (P < 0.05). 
Conclusions:  Acetaminophen and lidocaine reduced the incidence of withdrawal movement after rocuronium 
injection compared with saline.  (Korean J Anesthesiol 2010; 59: 13-16)
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Introduction
    Pain from the injection of rocuronium is a common side 
effect in anesthetic practice, with incidence of 50-80% [1,2]. 
The pain is at times severe, with a burning sensation [2,3]. 
Rocuronium injection pain can elicit withdrawal movement 
of the arm or generalized movement of the body, even after 
loss of consciousness, during induction of anesthesia [1,4]. 
These withdrawal movements may dislodge a venous catheter 
or cause injury during induction [5]. Pretreatment with 
midazolam, lidocaine, and ondansetron have been used in 
attempts to reduce this pain [4,6]. 
    Acetaminophen is widely used for pain management and anti-
pyresis as an alternative to aspirin and NSAIDsbut its action at 
the molecular level is remaining largely unknown. It is believed 
to be centrally active, producing analgesia and antipyresis 
by inhibiting cyclooxygenase (COX) in the hypothalamus 
[7]. From animal studies, its anti-nociceptive effects reflect a 
combination of peripheral and central actions resulting from 
COX-2 inhibition [8,9]. The peripheral action of acetaminophen 
suggests that IV acetaminophen with venous occlusion could 
decrease rocuronium injection pain and decrease the incidence 
of withdrawal movements. In this randomized, double-blind, 
placebo-controlled study, we aimed to compare the effect of IV 
acetaminophen with that of lidocaine to prevent rocuroinum-
induced withdrawal movements during the induction of 
anesthesia.
Materials and Methods 
    The Ethics Committee of our hospital approved the study 
protocol. Patients aged 19-69 years, of ASA physical status I and 
II, were randomly selected from all elective surgical lists using a 
random number generator (http://www.random.org), and 132 
patients were assessed for eligibility. Patients with chronic pain 
syndrome, neurological deficits, thrombophlebitis, difficult 
venous access, and clinical conditions that contraindicated 
the administration of any of the drugs used in the study were 
excluded. 
    After written informed consent was obtained, a total of 120 
patients were randomly allocated into 3 groups using a sealed 
envelope method - 120 sealed envelopes (40 for each group) 
containing the names of groups were prepared before study. 
None of the patients was premedicated before entering the 
operation room. On arrival in the operating room, patients 
were monitored with electrocardiogram, non-invasive 
arterial pressure, and pulse oximeter. A 20-gauge catheter was 
inserted into a superficial radial vein on the patient’s non-
dominant hand, and its position was confirmed by a free flow 
of lactated Ringer’s solution infusion by gravity. The lactated 
Ringer’s solution was infused at 100 ml/h for five minutes. 
After five minutes, the infusion was stopped and the arm with 
the IV line was elevated for 15 seconds for gravity drainage of 
venous blood. After occluding venous drainage using a rubber 
tourniquet on the upper arm, the patients were pretreated 
with test drug. An independent anesthetist prepared the 
solutions and the investigator was oblivious to the contents of 
the solutions. The test drug was administered over 10 seconds. 
Patients in group I (saline) received 5 ml normal saline, group 
II (lidocaine) received lidocaine 40 mg (0.8% lidocaine 5 
ml) and group III (acetaminophen) received 50 mg (5 ml) of 
acetaminophen (Perfalgan
Ⓡ, Bristol-Myers Squibb, France). We 
asked the patients if they felt any pain during injection of the 
test drug and the pain was assessed on a four-point scale: 0, no 
pain; 1, mild pain (pain reported only in response to questioning 
without any behavioral signs); 2, moderate pain (pain reported 
in response to questioning and accompanied by a behavioral 
signs); and 3, severe pain (strong vocal response or response 
accompanied by facial grimacing, arm withdrawal, or tears) [6].
    After 2 minutes, the rubber tourniquet was released and 
2.5% thiopental sodium 5 mg/kg was injected over 10-15 
seconds. Twenty seconds after the administration of thiopental, 
the anesthetist checked unconsciousness (as assessed by 
no verbal response and loss of the eyelash reflex). After loss 
of consciousness, 1% rocuronium (0.6 mg/kg) was injected 
over 5 seconds. During and after the injection of rocuronium, 
withdrawal movement was observed by the study-blinded 
investigator. Withdrawal movement was graded by the 
investigator according to the following scale: 1, no response; 
2, movement at wrist only; 3, movement/withdrawal involving 
arm only (elbow/shoulder); and 4, generalized response 
(movement/withdrawal in more than one extremity, cough, 
or breath holding) [4]. The anesthesia continued with an 
appropriate technique at the discretion of the attending 
anesthesiologist. Twenty-four hours after the operation, the 
injection site was checked for pain, edema, wheal, or flare 
response.
    A total of 118 patients were successfully examined in the study. 
Two patients were dropped due to difficulty of IV placement on 
dorsum of hand. Groups were similar with regard to age, weight, 
gender, and American Society of Anesthesiologist physical 
status (Table 1). 
    We estimated the incidence of withdrawal movement to be 
around 70% from other studies [2,4]. A power analysis indicated 
that a sample size of 37 in each group was sufficient to have 
80% power (Type II error β = 0.2) of detecting a 30% difference 
in incidence of withdrawal movement among the 3 groups at a 
95% significance level (Type I error α  = 0.05). To compensate 
for patient dropout, the sample size was increased to 40 patients 
per group.15 www.ekja.org
Korean J Anesthesiol Jeon, et al.
    Statistical analyses were performed using a statistical package 
(SPSS 13.0 for windows, SPSS Inc., Chicago, IL, USA). Data are 
presented as a mean (±SD) or number of patients. Demographic 
data were analyzed using the X
2 test and one-way analysis of 
variance. The incidence of pain on test drug injection and the 
incidence of withdrawal movement were analyzed using the 
Kruskal-Wallis test. Post hoc test were done by Mann-Whitney 
U test with Bonferroni correction. Statistical significance was 
defined as P < 0.05. 
Results
    The overall incidence of pain on pretreatment drug injection 
was 7.7% (3/39), 5.1% (2/39), and 2.5% (1/40) in groups I, II, 
and III, respectively (Table 2), with no significant difference 
between groups. The overall incidence of withdrawal movement 
after rocuronium injection (grade 2 or more) was 74.4% 
(29/39), 30.8% (12/39), and 35.0% (14/40) in groups I, II, and 
III, respectively (Table 3), with group II and group III showing 
significantly fewer withdrawal movements than group I (P = 
0.00). There were no significant differences in the degree of 
withdrawal movement between groups II and III. There were no 
complications, such as pain, edema, wheal, or flare, observed at 
the injection site within the first 24 hours after the operation in 
any of the treatment groups.
Discussion
    In this study, acetaminophen pretreatment with venous 
occlusion significantly reduced the incidence of rocuronium-
induced withdrawal movements, from 74.4% in the saline group 
to 35.0% in the acetaminophen group, similar to the 30.8% after 
lidocaine. This suggests that acetaminophen pretreatment 
also attenuated withdrawal movement during rocuronium 
injection to the same extent as lidocaine. The overall incidence 
of injection pain during drug pretreatment was 7.7%, 5.1%, 
and 2.5% in the saline, lidocaine, and acetaminophen groups, 
respectively, indicating that acetaminophen causes less 
injection pain and is suitable for pretreatment. 
    Peripheral veins are innervated with polymodal nociceptors 
that mediate pain responses to injected drugs [10]. Rocuronium 
is formulated using sodium acetate, sodium chloride, or 
acetic acid to produce a solution of pH 4, and therefore can 
cause burning pain and withdrawal movements. This pain 
may be caused by osmolality [11], pH of the solution [12], or 
local release of mediators such as kininogen cascade [13]. 
Rocuronium injection increases bradykinin concentrations 
in the skin [14], and the algogenic effect of rocuronium may 
result from direct activation of C-nociceptors with concomitant 
release of the calcitonin gene-related peptide (CGRP) and 
prostaglandin (PG) E2.
    Acetaminophen can act centrally, as PG production in the 
brain is 10 time more sensitive to inhibition by acetaminophen 
than that in the spleen [7], although later studies showed 
different tissue effects. For example, Swierkosz et al. [15] 
showed the greatest reduction of PG E2 synthesis was in the 
lung followed by the spleen and brain. Abbott and Hellemans 
[8] showed the analgesic effects of acetaminophen reflect 
central and peripheral actions. Lee et al. [16] showed that 
acetaminophen selectively suppresses peripheral PG E2 release 
and increases COX-2 gene expression in a clinical model of 
acute inflammation. Hinz et al. [9] showed acetaminophen 
inhibits COX-2 activity in human blood cells and suppresses 
PG E2 generation in human blood monocytes. Thus, 
acetaminophen inhibition of PGE2 may influence the intensity 
of rocuronium injection pain and withdrawal movements. 
    Tourniquet use is a common technique to minimize rocuro-
Table 1. Demographic Data
Groups
Group I
saline
(n = 39)
Group II
lidocaine
(n = 39)
Group III
acetaminophen
(n = 40)
Age (yr)
Sex 
ASA class (I/II)
Weight (kg)
45.4 ± 11.1
21/18
25/14
61.9 ± 9.7
45.9 ± 14.2
20/19
30/9
61.2 ± 8.8
50.1 ± 10.6
25/15
26/14
62.0 ± 8.3
Values are presented as either number of patients or mean ± SD.
Table 2. The Incidence and Characteristics of Pain during Injection 
of Pretreatment Solution
Severity of pain
Group I
saline
(n = 39)
Group II
lidocaine
(n = 39)
Group III
acetaminophen
(n = 40)
1 (No pain)
2 (Mild pain)
3 (Moderate pain)
4 (Severe pain)
Total frequency 
36 (92.3%)
1 (2.5%)
2 (5.1%)
0 (0%)
3 (7.7%)
37 (94.8%)
1 (2.5%)
1 (2.5%)
0 (0%)
2 (5.1%)
    39 (97.5%)
1 (5%)
0 (0%)
0 (0%)
    1 (2.5%)
Values are presented as number of patients (percentages).
Table 3. The Incidence and Characteristics of Withdrawal Movement 
Associated with Injection of Rocuronium
Grade of withdrawal 
movements
Group I
saline
(n = 39)
Group II
lidocaine
(n = 39)
Group III
acetaminophen
(n = 40)
1 (no response)
2 (wrist)
3 (Elbow/Shoulder)
4 (Generalized)
Total frequency
10 (25.6%)
12 (30.8%)
  9 (23.1%)
  8 (20.5%)
29 (74.4%)
27 (69.2%)*
3 (7.7%)*
   8 (20.5%)*
1 (2.6%)*
12 (30.8%)*
26 (65.0%)*
  4 (10.0%)*
  7 (17.5%)*
3 (7.5%)*
14 (35.5%)*
Values are presented as numbers of patients (percentages). *P < 0.05 
vs. Compared with Group I.16 www.ekja.org
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nium injection pain [4,6]. Shevchenko et al. [4] showed pre-
treatment with lidocaine and venous occlusion decreased the 
incidence of withdrawal movements to 46%. Memis et al. [6] 
showed that pretreatment of lidocaine with venous occlusion 
was more effective than ondansetron, tramadol, or fentanyl. 
Venous occlusion allows study of the peripheral action of drugs 
without a central effect, similar to a Bier block [17]. Huang et al. 
[18] showed that 10 mg ketorolac and longer venous occlusion 
(120 seconds, but not 30 or 60 seconds) reduced propofol 
injection pain. IV acetaminophen shows a systemic analgesic 
effect in 3 minutes [19], so we used a 120-second occlusion 
time. In our study, we used rubber tourniquet. That is easy to 
use, but it may have inconsistent pressure for different patients, 
a potential limitation of our study. 
    Lidocaine, a local anesthetic, reversibly blocks peripheral 
nerve pathways by blocking excitable membranes and is 
commonly used to reduce pain and withdrawal movements 
after rocuronium injection to 28-46% [4,6]. Here, lidocaine 
pretreatment decreased withdrawal movement to 30.8%. A 
novel ready-to-use formulation of intravenous acetaminophen 
does not cause pain on injection and offers improved local 
safety [20]. We did not find complications after pretreatment, 
and pain after IV injection of acetaminophen is normally 
2-4.1% [21,22], similar to our study (2.5%). 
    In conclusion, pretreatment with acetaminophen (50 mg) 
reduced the incidence of rocuronium-induced withdrawal 
movement as much as lidocaine. Further studies are required 
to determine the optimal dose of IV acetaminophen to control 
rocuronium-induced withdrawal movement and suppress 
CGRP and PG E2 release. 
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